Matches in SemOpenAlex for { <https://semopenalex.org/work/W4230482057> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W4230482057 abstract "Abstract Background . The ZINC trial randomized HIV-positive heavy drinkers to either daily zinc supplementation or placebo. The primary outcome was change in VACS index, a predictor of mortality, between baseline and 18 months. Because adherence and follow-up were suboptimal, the intention-to-treat analysis, which was not statistically significant, may have underestimated the effect of the zinc supplementation. Objective . We estimated the per-protocol effect of zinc versus placebo in the ZINC trial (i.e., the effect that would have been observed if all participants had had high adherence and none were lost to follow-up). Methods . Adherence was measured as the self-reported percentage of pills taken in the previous 6 weeks and assessed at all post-baseline visits. We used inverse probability weighting to estimate and compare the change in VACS index at 18 months in the zinc and placebo groups had all the trial participants had high adherence (i.e., cumulative adherence ≥80% at 18 months). To examine trends by level of adherence, we rerun the analyses using thresholds for high-adherence of 70% and 90% of average self-reported pill coverage. Results . The estimated (95% confidence interval) change in VACS index was –2.16 (-8.07, 3.59) and 5.84 (0.73, 11.80) under high adherence and no loss to follow-up in the zinc and placebo groups, respectively. The per-protocol effect estimate of the mean difference in change between the zinc and placebo group was -8.01 (-16.42, 0.01), somewhat larger than the intention-to-treat effect difference in change (-4.68 (-9.62, 0.25)), but it was still not statistically significant. The mean difference in change between individuals in the zinc and placebo group was -4.07 (-11.5,2.75) and -12.34 (-20.14,-4.14) for high adherence defined as 70% and 90% of pill-coverage, respectively. Conclusions . Overall, high adherence to zinc was associated with lower VACS score, but confidence intervals were wide and crossed 0. Further studies with larger sample size are needed to quantify the benefits of zinc supplementation in this population. Trial Registration . ClinicalTrials.gov Identifier: NCT01934803, August 30, 2013" @default.
- W4230482057 created "2022-05-11" @default.
- W4230482057 creator A5016411386 @default.
- W4230482057 creator A5022919303 @default.
- W4230482057 creator A5026540715 @default.
- W4230482057 creator A5030743581 @default.
- W4230482057 creator A5035462021 @default.
- W4230482057 creator A5040143635 @default.
- W4230482057 creator A5045565814 @default.
- W4230482057 creator A5066785906 @default.
- W4230482057 creator A5078774324 @default.
- W4230482057 date "2020-10-20" @default.
- W4230482057 modified "2023-10-11" @default.
- W4230482057 title "Per-Protocol Analysis of The ZINC Trial for HIV Disease Among Alcohol Users" @default.
- W4230482057 doi "https://doi.org/10.21203/rs.3.rs-33657/v1" @default.
- W4230482057 hasPublicationYear "2020" @default.
- W4230482057 type Work @default.
- W4230482057 citedByCount "0" @default.
- W4230482057 crossrefType "posted-content" @default.
- W4230482057 hasAuthorship W4230482057A5016411386 @default.
- W4230482057 hasAuthorship W4230482057A5022919303 @default.
- W4230482057 hasAuthorship W4230482057A5026540715 @default.
- W4230482057 hasAuthorship W4230482057A5030743581 @default.
- W4230482057 hasAuthorship W4230482057A5035462021 @default.
- W4230482057 hasAuthorship W4230482057A5040143635 @default.
- W4230482057 hasAuthorship W4230482057A5045565814 @default.
- W4230482057 hasAuthorship W4230482057A5066785906 @default.
- W4230482057 hasAuthorship W4230482057A5078774324 @default.
- W4230482057 hasBestOaLocation W42304820571 @default.
- W4230482057 hasConcept C126322002 @default.
- W4230482057 hasConcept C142724271 @default.
- W4230482057 hasConcept C168563851 @default.
- W4230482057 hasConcept C191897082 @default.
- W4230482057 hasConcept C192562407 @default.
- W4230482057 hasConcept C203014093 @default.
- W4230482057 hasConcept C204787440 @default.
- W4230482057 hasConcept C27081682 @default.
- W4230482057 hasConcept C3013748606 @default.
- W4230482057 hasConcept C44249647 @default.
- W4230482057 hasConcept C535196362 @default.
- W4230482057 hasConcept C71924100 @default.
- W4230482057 hasConcept C81603835 @default.
- W4230482057 hasConcept C98274493 @default.
- W4230482057 hasConceptScore W4230482057C126322002 @default.
- W4230482057 hasConceptScore W4230482057C142724271 @default.
- W4230482057 hasConceptScore W4230482057C168563851 @default.
- W4230482057 hasConceptScore W4230482057C191897082 @default.
- W4230482057 hasConceptScore W4230482057C192562407 @default.
- W4230482057 hasConceptScore W4230482057C203014093 @default.
- W4230482057 hasConceptScore W4230482057C204787440 @default.
- W4230482057 hasConceptScore W4230482057C27081682 @default.
- W4230482057 hasConceptScore W4230482057C3013748606 @default.
- W4230482057 hasConceptScore W4230482057C44249647 @default.
- W4230482057 hasConceptScore W4230482057C535196362 @default.
- W4230482057 hasConceptScore W4230482057C71924100 @default.
- W4230482057 hasConceptScore W4230482057C81603835 @default.
- W4230482057 hasConceptScore W4230482057C98274493 @default.
- W4230482057 hasLocation W42304820571 @default.
- W4230482057 hasOpenAccess W4230482057 @default.
- W4230482057 hasPrimaryLocation W42304820571 @default.
- W4230482057 hasRelatedWork W12291014 @default.
- W4230482057 hasRelatedWork W16388691 @default.
- W4230482057 hasRelatedWork W17083376 @default.
- W4230482057 hasRelatedWork W20986832 @default.
- W4230482057 hasRelatedWork W4141333 @default.
- W4230482057 hasRelatedWork W559902 @default.
- W4230482057 hasRelatedWork W6226196 @default.
- W4230482057 hasRelatedWork W12611928 @default.
- W4230482057 hasRelatedWork W13713547 @default.
- W4230482057 hasRelatedWork W6918129 @default.
- W4230482057 isParatext "false" @default.
- W4230482057 isRetracted "false" @default.
- W4230482057 workType "article" @default.